UBS Group AG Sells 510,322 Shares of Amneal Pharmaceuticals, Inc. $AMRX

UBS Group AG lessened its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 35.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 935,479 shares of the company’s stock after selling 510,322 shares during the quarter. UBS Group AG owned 0.30% of Amneal Pharmaceuticals worth $11,787,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in AMRX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Amneal Pharmaceuticals by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 94,638 shares of the company’s stock valued at $793,000 after buying an additional 4,178 shares in the last quarter. Millennium Management LLC lifted its holdings in Amneal Pharmaceuticals by 32.6% during the 1st quarter. Millennium Management LLC now owns 2,087,398 shares of the company’s stock valued at $17,492,000 after buying an additional 512,842 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Amneal Pharmaceuticals during the 1st quarter valued at about $244,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Amneal Pharmaceuticals by 5.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 334,956 shares of the company’s stock valued at $2,807,000 after buying an additional 16,536 shares in the last quarter. Finally, Creative Planning lifted its holdings in Amneal Pharmaceuticals by 61.9% during the 2nd quarter. Creative Planning now owns 23,896 shares of the company’s stock valued at $193,000 after buying an additional 9,136 shares in the last quarter. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

NASDAQ AMRX opened at $11.93 on Friday. The company has a market capitalization of $3.81 billion, a price-to-earnings ratio of 31.40 and a beta of 1.32. The company’s 50-day simple moving average is $12.65 and its two-hundred day simple moving average is $12.81. Amneal Pharmaceuticals, Inc. has a one year low of $7.02 and a one year high of $15.42.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its earnings results on Thursday, May 7th. The company reported $0.27 EPS for the quarter. The business had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. Equities analysts expect that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on AMRX. UBS Group began coverage on shares of Amneal Pharmaceuticals in a report on Friday, April 17th. They set a “buy” rating and a $19.00 price objective for the company. Truist Financial lifted their price objective on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Zacks Research lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Finally, Weiss Ratings upgraded shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the transaction, the director owned 93,660 shares of the company’s stock, valued at approximately $1,211,960.40. This trade represents a 27.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.